glp 1 agonist retatrutide Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA What Is Retatrutide? The Triple
Description
While their metabolic benefits are well known, their potential to directly influence intracranial pressure may be even more significant

Wu Q, Li D, Huang C, et al

A generalized GLP-1RA use has been explored across different clinical pathologies, although most of the literature narrated does not explore effects of GLP-1RA on diabetics and non-diabetics with concomitant renal and liver dysfunctions

GLP-1 receptor agonists and DPP4-inhibitor direct the T2DM therapies

Nat Med 11: 90-94, 2005

Accessed September 19, 2018
